|
Feb 15
|
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns
|
|
Feb 15
|
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock
|
|
Feb 14
|
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
|
|
Feb 10
|
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
|
|
Feb 10
|
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
|
|
Feb 10
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024
|
|
Oct 2
|
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
|
|
Sep 27
|
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
|
|
Sep 26
|
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)
|
|
Sep 3
|
Enanta Pharmaceuticals to Participate in Investor Conferences in September
|
|
May 29
|
Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
|
|
May 8
|
Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
May 7
|
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
|
|
May 7
|
Q2 2024 Enanta Pharmaceuticals Inc Earnings Call
|
|
May 7
|
Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference
|
|
May 7
|
Enanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 6
|
Enanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst Expectations
|
|
May 6
|
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
|
|
May 6
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
|
|
May 3
|
Strong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year loss
|